Phase II study of amonafide in advanced pancreatic adenocarcinoma

✍ Scribed by Kaye Linke; Richard Pazdur; James L. Abbruzzese; Jaffer A. Ajani; Rodger Winn; James E. Bradof; Karen Daugherty; Bernard Levin

• Publisher: Springer US
• Year: 1991
• Tongue: English
• Weight: 262 KB
• Volume: 9
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/bf00183580

✦ Synopsis

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m 2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/mL Of the 15 patients, 14 were evaiuable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m 2, 3 of 12 courses at 350 mg/m 2 and in 1 of 4 courses at 300 mg/mL Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m 2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.